Adaptive Biotechnologies
Adaptive Biotechnologies Lays out Strategy to Drive ClonoSeq Adoption
The Seattle-based immune sequencing firm reported a 46 percent increase in fourth quarter revenues, about equally split between its MRD and immune medicine businesses.
JP Morgan Healthcare Conference, Day 1: Guardant Health, Exact Sciences, QuidelOrtho, More
Highlights from the first day included Exact Sciences' profitability forecast, an update on QuidelOrtho's integration, and Guardant Health's "quantum leap forward" with its "smart" liquid biopsy platform.
Adaptive Bio Narrows 2022 Revenue Guidance, Outlines Financial Expectations
Releasing Q3 results, the Seattle-based immune system biotechnologies firm set its new full-year revenue guidance to the range of $185 million to $190 million.
Adaptive Biotechnologies Inks Partnership to Integrate MRD Assay With Epic's EMR System
After the expected integration in 2023, providers can order Adaptive’s ClonoSeq assay and review the results using the Epic electronic medical record system.
Adaptive Biotechnologies Inks Financing Deal Worth up to $250M
The Seattle-based biotech company will receive the money in exchange for a percentage of its GAAP revenues.